PBMC Gene Expression Biomarkers for Hepatitis B Peg-IFN-α Treatment Response

A prospective clinical study of HBeAg-negative chronic hepatitis B patients treated with Peg-IFN-α for 48 weeks. The dataset likely contains mRNA expression levels of ADAR1, N4BP1, and PSME1 in peripheral blood mononuclear cells (PBMCs) measured at multiple time points, correlated with virological and serological response outcomes. The study, authored by Hao Pang and published on figshare under CC-BY-4.0, reports response rates of 47.25% (VR) and 35.16% (SR).

Use Cases

• Predicting virological response to Peg-IFN-α treatment based on ADAR1, N4BP1, and PSME1 mRNA levels.
• Assessing the diagnostic performance of gene expression biomarkers using ROC curve analysis.
• Identifying early indicators of HBsAg clearance based on dynamic changes in biomarker expression.
• Conducting multivariate analysis to find independent associations between biomarkers and therapeutic response.

Strengths

• Includes specific performance metrics for biomarkers, such as AUC values up to 0.9230 for ADAR1.
• Reports concrete clinical response rates: 47.25% virological response and 35.16% serological response.
• Data is from a prospective study with a defined 48-week follow-up period.

Limitations

• Row count is unknown, which may limit suitability assessment.
• Column-level documentation is absent; field semantics must be inferred after download.
• The dataset is very small at 25.6 KB, indicating limited scope.

Provenance

Source

figshare, author Hao Pang.

Collection Method

Prospective clinical study using real-time quantitative PCR to measure mRNA levels in PBMCs.

Time Range

Treatment and follow-up period of 48 weeks.

Freshness

Last updated 2026-04-13 04:36:10; freshness should be verified.

Geography

null